Bladder Cancer

Latest News

Cretostimogene Grenadenorepvec plus pembrolizumab sustains high CR rate in NMIBC
Cretostimogene Grenadenorepvec plus pembrolizumab sustains high CR rate in NMIBC

June 5th 2024

“CORE-001’s excellent efficacy, long-term durability of response, and favorable benefit-to-risk-ratio profile seen with combination cretostimogene and pembrolizumab suggest the potential for a novel bladder-sparing therapy in the BCG-unresponsive NMIBC setting,” said Roger Li, MD.

Sacituzumab govitecan falls short in phase 3 trial for metastatic urothelial carcinoma
Sacituzumab govitecan falls short in phase 3 trial for metastatic urothelial carcinoma

May 31st 2024

Nivolumab plus chemotherapy approved in EU for urothelial carcinoma
Nivolumab plus chemotherapy approved in EU for urothelial carcinoma

May 29th 2024

Expert discusses gender disparities in bladder cancer care
Expert discusses gender disparities in bladder cancer care

May 27th 2024

FDA grants Fast Track Designation to RAG-01 in NMIBC
FDA grants Fast Track Designation to RAG-01 in NMIBC

May 21st 2024

More News

© 2024 MJH Life Sciences

All rights reserved.